Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
47.45
Dollar change
-1.55
Percentage change
-3.16
%
IndexRUT P/E- EPS (ttm)-2.87 Insider Own35.68% Shs Outstand53.71M Perf Week4.26%
Market Cap2.55B Forward P/E- EPS next Y-2.17 Insider Trans-4.43% Shs Float34.55M Perf Month178.79%
Income-102.77M PEG- EPS next Q-0.50 Inst Own61.47% Short Float19.14% Perf Quarter250.70%
Sales0.00M P/S- EPS this Y34.87% Inst Trans1.83% Short Ratio6.01 Perf Half Y168.08%
Book/sh2.78 P/B17.04 EPS next Y0.72% ROA-66.96% Short Interest6.61M Perf Year505.23%
Cash/sh2.98 P/C15.93 EPS next 5Y- ROE-89.59% 52W Range5.95 - 49.87 Perf YTD208.52%
Dividend Est.- P/FCF- EPS past 5Y- ROI-68.19% 52W High-4.85% Beta1.12
Dividend TTM- Quick Ratio6.64 Sales past 5Y0.00% Gross Margin- 52W Low697.48% ATR (14)3.09
Dividend Ex-Date- Current Ratio6.64 EPS Y/Y TTM2.66% Oper. Margin0.00% RSI (14)75.44 Volatility7.42% 10.25%
Employees46 Debt/Eq0.24 Sales Y/Y TTM- Profit Margin- Recom1.36 Target Price31.88
Option/ShortYes / Yes LT Debt/Eq0.22 EPS Q/Q50.02% Payout- Rel Volume0.82 Prev Close49.00
Sales Surprise- EPS Surprise13.24% Sales Q/Q- EarningsNov 09 BMO Avg Volume1.10M Price47.45
SMA2019.76% SMA5086.07% SMA200183.77% Trades Volume899,006 Change-3.16%
Date Action Analyst Rating Change Price Target Change
Jan-25-24Initiated Oppenheimer Outperform $26
Jan-08-24Initiated Cantor Fitzgerald Overweight
Dec-18-23Initiated Raymond James Outperform $29
Nov-10-23Upgrade Jefferies Hold → Buy $18 → $26
Aug-16-23Initiated Guggenheim Buy $27
Jan-04-23Downgrade Wedbush Outperform → Neutral $33 → $8
Jan-04-23Downgrade Jefferies Buy → Hold $32 → $6
Jul-12-22Initiated JP Morgan Overweight $35
May-02-22Initiated H.C. Wainwright Buy $35
Apr-19-22Initiated Wedbush Outperform $32
Feb-02-24 12:40PM
08:00AM
Feb-01-24 04:05PM
Jan-29-24 11:50PM
06:15AM
06:30AM Loading…
Jan-25-24 06:30AM
Jan-12-24 06:44PM
Jan-08-24 08:01AM
08:00AM
Dec-27-23 08:00AM
Dec-15-23 10:15AM
Nov-14-23 05:05PM
09:55AM
Nov-09-23 09:29AM
08:00AM
10:00AM Loading…
Nov-04-23 10:00AM
Oct-30-23 08:00AM
Oct-18-23 09:35AM
Oct-17-23 09:35AM
Oct-16-23 09:35AM
Oct-13-23 10:22AM
Sep-26-23 04:02PM
Aug-31-23 08:00AM
Aug-16-23 10:00AM
Aug-15-23 04:03PM
Aug-10-23 08:00AM
Aug-04-23 06:30PM
Jul-24-23 09:01AM
Jul-07-23 06:35PM
Jun-27-23 08:05AM
07:04PM Loading…
Jun-20-23 07:04PM
09:33AM
Jun-17-23 10:10AM
Jun-15-23 04:44PM
Jun-12-23 12:05PM
Jun-11-23 01:08PM
Jun-08-23 08:00AM
Jun-07-23 08:00AM
May-11-23 08:36AM
07:30AM
May-04-23 08:00AM
Mar-28-23 07:30AM
Feb-27-23 04:05PM
Feb-14-23 07:48AM
Feb-09-23 06:51AM
05:54AM
Feb-06-23 04:05PM
Feb-01-23 09:52PM
04:01PM
Jan-30-23 07:35AM
06:00AM
Jan-25-23 08:00AM
Jan-22-23 07:39AM
Jan-06-23 05:02AM
Jan-04-23 04:07PM
12:20PM
10:22AM
06:52AM
Jan-03-23 04:01PM
Dec-20-22 04:05PM
Nov-25-22 07:38AM
Nov-22-22 07:30AM
Nov-17-22 07:30AM
Nov-09-22 07:30AM
Nov-05-22 04:50PM
Oct-17-22 07:30AM
Sep-15-22 09:55AM
Sep-07-22 07:30AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-10-22 07:30AM
Aug-04-22 07:30AM
Jul-06-22 07:30AM
Jun-18-22 08:20AM
Jun-04-22 02:30PM
Jun-02-22 07:30AM
May-20-22 04:05PM
May-16-22 07:30AM
May-05-22 04:05PM
May-03-22 04:33PM
May-02-22 07:06PM
Apr-12-22 07:30AM
Mar-24-22 06:30AM
Mar-21-22 07:30AM
Mar-17-22 07:30AM
Mar-01-22 07:30AM
Feb-22-22 05:29AM
Feb-14-22 04:01PM
Feb-10-22 08:46AM
Feb-07-22 05:24PM
Jan-18-22 07:30AM
Jan-04-22 07:30AM
Dec-20-21 07:26PM
Dec-17-21 07:54AM
07:30AM
Dec-14-21 07:30AM
Nov-10-21 04:15PM
07:15AM
Nov-04-21 04:05PM
Oct-13-21 07:30AM
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Katabi MahaDirectorJan 30Buy31.00161,2904,999,9903,628,446Feb 01 05:58 PM
COMMODORE CAPITAL LP10% OwnerJan 10Sale18.001,050,00018,900,0004,400,000Jan 12 09:55 PM
Fordyce MarshallPresident and CEODec 29Option Exercise2.8713,51638,854256,877Jan 03 04:15 PM
Fordyce MarshallPresident and CEOAug 21Sale16.665,21086,779243,361Aug 23 05:56 PM
Curley JoanneChief Development OfficerAug 21Sale16.661,49024,81726,962Aug 23 05:57 PM
Lin CeliaChief Medical OfficerAug 21Sale16.651,49024,81611,010Aug 23 05:59 PM
Young Joseph RSVP, Finance, Chief Acct OffcrJul 05Option Exercise3.9410,00039,39632,679Jul 06 04:05 PM
Grant SeanChief Financial OfficerJun 23Buy16.605,00083,0005,992Jun 23 04:05 PM
COMMODORE CAPITAL LP10% OwnerJun 20Buy15.17448,2176,799,0045,450,000Jun 22 04:10 PM
SEIDENBERG BETH CDirectorMar 30Buy7.242,30016,6511,949,295Apr 03 04:05 PM
SEIDENBERG BETH CDirectorMar 28Buy7.2423,908173,1921,946,995Mar 30 04:07 PM
SEIDENBERG BETH CDirectorMar 27Buy7.241,63311,8301,923,087Mar 28 04:05 PM
SEIDENBERG BETH CDirectorMar 24Buy7.241,83313,2721,921,454Mar 28 04:05 PM
SEIDENBERG BETH CDirectorMar 20Buy7.2115,252110,0331,919,621Mar 21 04:40 PM
SEIDENBERG BETH CDirectorMar 17Buy7.1274,045526,8821,904,369Mar 21 04:40 PM
SEIDENBERG BETH CDirectorMar 16Buy7.0960,097426,2681,830,324Mar 17 04:10 PM
SEIDENBERG BETH CDirectorMar 15Buy7.1232,844234,0101,770,227Mar 17 04:10 PM
SEIDENBERG BETH CDirectorMar 10Buy7.1648,003343,4851,737,383Mar 14 04:05 PM
SEIDENBERG BETH CDirectorMar 03Buy7.251,0007,2451,689,380Mar 07 04:07 PM
SEIDENBERG BETH CDirectorMar 02Buy7.2423,378169,3221,688,380Mar 03 04:07 PM
SEIDENBERG BETH CDirectorMar 01Buy7.251007251,665,002Mar 03 04:07 PM